Today: 21 May 2026
P&G stock price heads into Monday on JPMorgan upgrade as Fed week looms
25 January 2026
1 min read

P&G stock price heads into Monday on JPMorgan upgrade as Fed week looms

NEW YORK, Jan 25, 2026, 11:19 AM EST — Market closed.

  • JPMorgan raised its price target for Procter & Gamble, joining Wells Fargo and UBS in boosting their own estimates.
  • PG shares closed Friday at $150.15, with U.S. markets offline for the weekend.
  • This week’s Fed decision and crucial consumer data have investors focused on what’s next.

JPMorgan lifted Procter & Gamble to Overweight from Neutral, boosting its price target to $165 from $157, TheFly reports. P&G shares closed Friday at $150.15, up 0.15%, and will resume trading when markets open Monday.

The timing is crucial. P&G remains a core holding for numerous funds, often drawing capital from investors seeking reliable earnings—even if growth tapers off.

The quarter revealed a clear tension within the business — prices stayed firm, but demand weakened. P&G reported “organic sales” — which exclude currency effects and acquisitions or divestitures — were flat. Core earnings per share, adjusted for one-time items, came in at $1.88. CEO Shailesh Jejurikar confirmed the company is still on track to meet its fiscal-year guidance. Procter & Gamble

JPMorgan analyst Andrea Teixeira expects P&G to pick up organic sales growth and boost margins, saying the “worst seems behind” following increased investment. She added, “We give PG the benefit of the doubt,” though she warned of execution risks tied to regaining market share. Investors.com

Wells Fargo’s Chris Carey bumped his price target on Procter & Gamble to $165 from $158, maintaining an Overweight rating. Carey noted, “If U.S. data improves, Procter & Gamble works,” highlighting the “if” as the key uncertainty. TipRanks

UBS bumped its price target to $170 from $161 and stuck with a Buy rating, noting that P&G beat estimates in the second quarter while maintaining its fiscal 2026 guidance.

In its latest quarterly filing, P&G revealed it repurchased around $2.3 billion in shares and paid a dividend of $1.0568 per share. The company also flagged tariff expenses and product mix as headwinds impacting gross margin in certain segments.

Traders are now eyeing whether the stock can stay above $150 without a new catalyst. P&G’s lineup — including Tide, Pampers and Gillette — is closely tied to consumer behavior, and its pricing and volume trends could ripple through peers like Kimberly-Clark, Colgate-Palmolive and Unilever.

The boost from upgrades could vanish quickly if U.S. consumer spending remains weak, retailers resist raising prices, or costs surge again. Rising rates wouldn’t offer relief either; dividend-heavy defensive stocks tend to stumble as bond yields climb.

The key event this week is the Federal Reserve’s policy announcement on Wednesday, Jan. 28, set for 2 p.m. ET, followed by Chair Jerome Powell’s press briefing at 2:30 p.m. ET. On Tuesday, the U.S. consumer confidence report drops at 10 a.m. ET.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next
Previous Story

Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next

NextEra Energy stock price: NEE set for earnings-week test after insider sale filing
Next Story

NextEra Energy stock price: NEE set for earnings-week test after insider sale filing

Go toTop